Current and novel treatment approaches for first-line EGFR-m NSCLC

Current and novel treatment approaches for first-line EGFR-m NSCLC

New FDA-Approved Treatment for EGFRm NSCLC First-line! 🙌 Groundbreaking ApproachПодробнее

New FDA-Approved Treatment for EGFRm NSCLC First-line! 🙌 Groundbreaking Approach

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

2023 Best of Lung: Targeted Therapies in Lung Cancer

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLCПодробнее

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

Facilitating Progress in the Treatment of SCLCПодробнее

Facilitating Progress in the Treatment of SCLC

Targeted treatment with EGFR TKIs: Front line optionsПодробнее

Targeted treatment with EGFR TKIs: Front line options

Novel therapy for Lung Cancer: From targeted therapy to immuno-therapy and back again!Подробнее

Novel therapy for Lung Cancer: From targeted therapy to immuno-therapy and back again!

TKI-resistant EGFR-mutant NSCLCПодробнее

TKI-resistant EGFR-mutant NSCLC

Mechanisms of Resistance to EGFR TKI and New Treatment StrategiesПодробнее

Mechanisms of Resistance to EGFR TKI and New Treatment Strategies